CloneID: 5F11
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was raised by immunzing mice expressing human antibodies with human CD30.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent™ antibody, based on the original human IgG format, created for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P28908
Specificity Statement: This antibody is specific for human CD30
Application Notes (Clone): The original antibody was used for an ELISA on recombinant CD30-Fc fusion protein. This antibody was used for flow cytometry on Hodgkin tumor cell line L540 and on the CD30 line Daudi. This antibody was used for surface plasmon resonance on the antigen sCD30-Fc. The capacity of the antibody to mediate lysis of CD30-expressing tumor cells was investigated using a 51Cr-release assay. It showed the ability to lyse these cells (Borchmann et al., 2003; PMID:12881320). The ability of this antibody to inhibit growth of tumor cells in vitro was demonstrated by a cell viability assay using XTT (Böll et al., 2005; PMID:15878978, Borchmann et al., 2003; PMID:12881320). A clear and dose-dependent effect on cell metabolism could be observed. This antibody was tested in vivo on CD30 expressing human tumors. CD30 expressing human tumors were established in SCID mice then the mice were treated with this antibody. The antibody showed substantial tumor regression and in some cases complete disappearance (Borchmann et al., 2003; PMID:12881320). The antibody was used while comparing the subcellular distribution of NF-κB in the untreated Hodgkin cell line L540 and after incubation with this antibody. It showed that the antibody activated NF-kappaB and c-flip. This antibody was used in vivo on L540-derived tumor-bearing mice, it showed that combining this antibody with bortezomib showed tumor regression (Böll et al., 2005; PMID:15878978). An CAR of this antibody was used in vivo on immunocompromised NSG mice with CD30+ HH cell tumors. It showed a suppression on tumor growth in these experiments. In vitro this antibody also shows in increase in cytokine released if the cells expressing the antibody are cultured together with cells expressing CD30 (Choi et al., 2021; PMID:33287637).
English
Deutsch
